Evaluation of FreeStyle Libre Flash Glucose Monitoring System on Glycemic Control, Health-Related Quality of Life, and Fear of Hypoglycemia in Patients with Type 1 Diabetes

Ayman A Al Hayek, Asirvatham A Robert, Mohamed A Al Dawish, Ayman A Al Hayek, Asirvatham A Robert, Mohamed A Al Dawish

Abstract

Background/objectives: In the current era of modern technology and the development of smart devices such as the flash glucose monitoring (FGM) systems, patients can easily monitor their glucose levels more frequently without any inconvenience. In this study, we evaluate the effect of FreeStyle Libre FGM system on glycemic control, hypoglycemia, health-related quality of life (QoL), and the fear of hypoglycemia (FOH) among children and young people with type 1 diabetes (T1D).

Design and methods: A prospective study was conducted at the Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, between January 2017 and May 2017 on 47 (aged 13-19 years) registered patients with T1D who used conventional finger-pricking method for self-testing the glucose. At baseline visit, the FGM sensors were placed on each participant by a trained diabetes educator. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total number of scans conducted during the study period. At the baseline and at 3 months of the experiment, a trained interviewer administered the questionnaire Hypoglycemia Fear Survey-Child Version (HFS-C) and PedsQL 3.0 (QoL questionnaire) to each patient. The age, sex, weight, height, adjusted body mass index, duration of diabetes, treatment modality, and glycosylated hemoglobin A1c (HbA1c) levels of each patient were recorded.

Results: As compared with the baseline, a significant improvement was noted in the behavior of FOH (P = .0001), worry (P = .0001), QoL (P = .002), HbA1c level (P = .008), and hypoglycemia (P = .023) at 3 months. Significant improvement was noted in the behavior (P = .0001), worry (P = .0001), QoL (P = .003), HbA1c level (P = .014), and hypoglycemia (P = .001) among the multiple-dose insulin injection-treated patients as compared with baseline. Significant improvement was noted in the behavior (P = .0001), worry (P = .0001), and hypoglycemia (P = .001) among the insulin pump-treated patients as compared with baseline. A positive correlation was recorded in the behavior (r = .47; P < .001), QoL (r = .70; P < .001), and the mean number of FGM scans. A negative correlation was recorded in the worry (r = -.43; P = .002), HbA1c level (r = -.58; P < .001), hypoglycemia (r = -.65; P < .001), and the mean number of FGM scans.

Conclusions: The frequent use of FGM scanning reduced the frequency of hypoglycemia, HbA1c level, and worry and increased the behavior and QoL. As compared with self-testing by the conventional finger-pricking method, the use of FGM increased the frequency of self-testing and thus diabetes control.

Keywords: FreeStyle Libre; fear of hypoglycemia; glucose monitoring; glycemic control; hypoglycemia; type 1 diabetes.

Conflict of interest statement

Declaration Of Conflicting Interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Selvan C, Thukral A, Dutta D, Ghosh S, Chowdhury S. Impact of self-monitoring of blood glucose log reliability on long-term glycemic outcomes in children with type 1 diabetes. Indian J Endocrinol Metab. 2017;21:382–386.
    1. Robert AA, Al Dawish MA, Braham R, Musallam MA, Al Hayek AA, Al Kahtany NH. Type 2 diabetes mellitus in Saudi Arabia: major challenges and possible solutions. Curr Diabetes Rev. 2017;13:59–64.
    1. Cemeroglu AP, Can A, Davis AT, et al. Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr Pract. 2015;21:46–53.
    1. Al Hayek AA, Robert AA, Babli S, Almonea K, Al Dawish MA. Fear of self-injecting and self-testing and the related risk factors in adolescents with type 1 diabetes: a cross-sectional study. Diabetes Ther. 2017;8:75–83.
    1. Ahlen E, Pivodic A, Wedel H, et al. Current smoking in relation to excess risk of mortality in persons with type 1 diabetes. J Diabetes Sci Technol. 2016;10:1006–1014.
    1. Hunt CW. Technology and diabetes self-management: an integrative review. World J Diabetes. 2015;6:225–233.
    1. Herman A, Aerts O, Baeck M, et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor. Contact Dermatitis. 2017;77:367–373.
    1. Ratna S, Subashini R, Unnikrishnan R, Mohan V. Use of Freestyle Libre ProTM flash glucose monitoring system in different clinical situations at a diabetes centre. J Assoc Physicians India. 2017;65:18–23.
    1. Hoss U, Budiman ES. Factory-calibrated continuous glucose sensors: the science behind the technology. Diabetes Technol Ther. 2017;19:S44–S50.
    1. Slattery D, Choudhary P. Clinical use of continuous glucose monitoring in adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:S55–S61.
    1. Edge J, Acerini C, Campbell F, et al. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child. 2017;102:543–549.
    1. Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–794.
    1. Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP. Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. J Endocrinol Invest. 2016;39:1391–1399.
    1. Dover AR, Stimson RH, Zammitt NN, Gibb FW. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol. 2017;11:442–443.
    1. Distiller LA, Cranston I, Mazze R. First clinical experience with retrospective flash glucose monitoring (FGM) analysis in South Africa: characterizing glycemic control with ambulatory glucose profile. J Diabetes Sci Technol. 2016;10: 1294–1302.
    1. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.
    1. Al Hayek AA, Robert AA, Braham RB, Issa BA, Al Sabaan FS. Predictive risk factors for fear of hypoglycemia and anxiety-related emotional disorders among adolescents with type 1 diabetes. Med Princ Pract. 2015;24:222–230.
    1. Gonder-Frederick LA, Fisher CD, Ritterband LM, et al. Predictors of fear of hypoglycemia in adolescents with type 1 diabetes and their parents. Pediatr Diabetes. 2006;7:215–222.
    1. Al-Hayek AA, Robert AA, Abbas HM, et al. Assessment of health-related quality of life among adolescents with type 1 diabetes mellitus in Saudi Arabia. Saudi Med J. 2014;35:712–717.
    1. Abdul-Rasoul M, AlOtaibi F, Abdulla A, Rahme Z, AlShawaf F. Quality of life of children and adolescents with type 1 diabetes in Kuwait. Med Princ Pract. 2013;22:379–384.
    1. National Collaborating Centre for Women’s and Children’s Health. Diagnosis and Management of Type 1 Diabetes in Children and Young People (Clinical Guidance). London, England: RCOG Press National Collaborating Centre for Women’s and Children’s Health; 2004.
    1. National Collaborating Centre for Women’s and Children’s Health. Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management (Clinical Guidance). London, England: National Institute for Health and Care Excellence (UK); National Collaborating Centre for Women’s and Children’s Health; 2015.
    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32:S1–S201.
    1. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36:S11–S66.
    1. Hainsworth T. NICE guidance on diagnosis and management of type 1 diabetes. Nurs Times. 2004;100:28–29.
    1. McIntosh B, Yu C, Lal A, et al. Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Med. 2010;4:e102–e113.
    1. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care. 1982;5:479–484.
    1. Sekido K, Sekido T, Kaneko A, et al. Careful readings for a flash glucose monitoring system in nondiabetic Japanese subjects: individual differences and discrepancy in glucose concentrarion after glucose loading (Rapid Communication). Endocr J. 2017;34:827–832.
    1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–2263.
    1. Paula JS, Braga LD, Moreira RO, Kupfer R. Correlation between parameters of self-monitoring of blood glucose and the perception of health-related quality of life in patients with type 1 diabetes mellitus. Arch Endocrinol Metab. 2016;61:343–347.
    1. Gonder-Frederick L, Nyer M, Shepard JA, Vajda K, Clarke W. Assessing fear of hypoglycemia in children with type 1 diabetes and their parents. Diabetes Manag (Lond). 2011;1:627–639.
    1. Harris MI, Cowie CC, Howie LJ. Self-monitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care. 1993;16:1116–1123.
    1. Scorpiglione N, el-Shazly M, Abdel-Fattah M, et al. Epidemiology and determinants of blood glucose self-monitoring in clinical practice. Diabetes Res Clin Pract. 1996;34:115–125.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren